

Applications will be accepted from both for-profit and non-profit entities that satisfy the eligibility criteria set forth in the TTA NOFO.

*Statutory Authority:* Sections 803, 804, and 814 of NAPA, as amended (42 U.S.C. 2991b, 2991c, 2992b–1).

**Hope MacDonald Lone Tree,**

*Deputy Commissioner, Administration for Native Americans, Administration for Children and Families.*

[FR Doc. 2026–05484 Filed 3–19–26; 8:45 am]

**BILLING CODE 4184–34–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:** Inquiries related to this licensing opportunity should be directed to: David Yang at 240–695–6406, or *David.Yang@niaid.nih.gov*. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

**SUPPLEMENTARY INFORMATION:** Technology description follows:

**Gene Editing for ALPK1 p.Thr237Met**

*Description of Technology:* ROSAH syndrome is a rare genetic disease caused by a mutation in the human alpha kinase 1 (ALPK1) gene (p.Thr237Met), leading to vision loss, swollen optic nerves, dry mouth, enlarged spleen, and frequent headaches. Researchers in the

Laboratory of Clinical Immunology and Microbiology (LCIM) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach that can precisely fix the ALPK1 mutation without causing unwanted changes in the patient's DNA. This method uses a base editor combined with a guide RNA to safely and efficiently convert the pathogenic thymine of the mutation back to cytosine. In laboratory tests, this gene editing technology successfully repaired the mutation in patient-derived affected cells with high accuracy and no side effects.

This therapy could be delivered directly to the eye or salivary glands, or patient cells could be corrected outside the body and then returned to the patient, offering hope for personalized treatment to restore vision and improve quality of life for people with ROSAH syndrome.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

*Potential Commercial Applications:*

- Personalized therapy for individuals with disease secondary to the ALPK1 p.Thr237Met genetic variant.

*Competitive Advantages:*

- Highly accurate tool that directly repairs the faulty gene that causes ROSAH syndrome, while avoiding unwanted changes elsewhere in DNA.
- Corrects the mutation in most patient cells with few or no mistakes.
- Can be delivered directly to affected areas (e.g., eye or salivary glands) or can treat patient cells outside the body.
- Custom therapy for people with the ALPK1 mutation.
- Effective in cells that don't divide, unlike older gene editing methods.

*Development Stage:*

- Pre-Clinical.

*Inventors:* Dr. Christina Torres Kozycki, Dr. Colin L. Sweeney, Dr. Uimook Choi, all of NIAID.

*Intellectual Property:* HHS Reference No. E–044–2024–0. Provisional Patent Application No. 63/733,836, filed on December 13, 2024, and PCT Patent Application No. PCT/US2025/059432, filed on December 12, 2025.

*Licensing Contact:* To license this technology, please contact David Yang at 240–695–6406, or *David.Yang@niaid.nih.gov*, and reference E–044–2024–0.

*Research Opportunity:* The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to

further develop, evaluate, or commercialize this technology. Area of specific interest includes human clinical trials. For collaboration opportunities, please contact David Yang at 240–695–6406, or *David.Yang@niaid.nih.gov*.

Dated: March 18, 2026.

**Surekha Vathyam,**

*Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.*

[FR Doc. 2026–05527 Filed 3–19–26; 8:45 am]

**BILLING CODE 4140–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Center for Scientific Review; Notice of Closed Meetings**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Contracts: Support for Evaluating and Conducting Computational and Alternative Toxicological Methods for the National Institute of Environmental Health Sciences.

*Date:* April 16, 2026.

*Time:* 10:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Leroy Worth, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, Keystone Building 3082, Research Triangle Park, NC 27709, 984–287–3340, *worth@niehs.nih.gov*.

*Name of Committee:* Applied Immunology and Disease Control Integrated Review Group; Transmission of Vector-Borne and Zoonotic Diseases Study Section.

*Date:* April 16, 2026.

*Time:* 10:00 a.m. to 9:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.  
*Contact Person:* Haruhiko Murata, Ph.D., Scientific Review Officer, Center for Scientific Review, 6701 Rockledge Drive, National Institutes of Health, Bethesda, MD 20892, 301-594-3245, [muratah@csr.nih.gov](mailto:muratah@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Auditory and Pain Mechanisms.

*Date:* April 16, 2026.

*Time:* 10:00 a.m. to 7:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Nesar Uddin Akanda, Ph.D., MD, Scientific Review Officer, Center for Scientific Review, 6701 Rockledge Drive, Room 1011-B, National Institutes of Health, Bethesda, MD 20892, 301-594-8984, [nesar.akanda@nih.gov](mailto:nesar.akanda@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Support for Research Excellence-SuRE and SuRE-First Study Section Meeting.

*Date:* April 16, 2026.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Dawanna James-Holly, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301-480-2776, [dawanna.james-holly@nih.gov](mailto:dawanna.james-holly@nih.gov).

*Name of Committee:* Infectious Diseases and Immunology A Integrated Review Group; Bacterial Virulence Study Section.

*Date:* April 16, 2026.

*Time:* 10:00 a.m. to 7:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Susan Daum, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3202, Bethesda, MD 20892, 301-827-7233, [susan.boyle-vavra@nih.gov](mailto:susan.boyle-vavra@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Special Topics in Genomics and Therapeutics for Genetic Diseases.

*Date:* April 16, 2026.

*Time:* 10:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Dharmendar Rathore, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 912-D, Bethesda, MD 20892, 301-402-6965, [dharmendar.rathore@nih.gov](mailto:dharmendar.rathore@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; RFA-RM-24-008: Limited Competition: Competing Revisions to Support Clinical Trials in Somatic Cell Genome Editing (U19 Clinical Trial Required).

*Date:* April 16, 2026.

*Time:* 12:30 p.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Mollie Kim Manier, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 900-E, Bethesda, MD 20892, 301-594-0510, [mollie.manier@nih.gov](mailto:mollie.manier@nih.gov).

*Name of Committee:* Population Sciences and Epidemiology Integrated Review Group; Aging, Injury, Musculoskeletal, and Rheumatologic Disorders Study Section.

*Date:* April 17, 2026.

*Time:* 9:00 a.m. to 8:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Nketi I. Forbang, MD, MPH, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1006K1, Bethesda, MD 20892, 301-594-0357, [forbangni@csr.nih.gov](mailto:forbangni@csr.nih.gov).

*Name of Committee:* Cardiovascular and Respiratory Sciences Integrated Review Group; Integrative Myocardial Physiology/ Pathophysiology B Study Section.

*Date:* April 17, 2026.

*Time:* 9:00 a.m. to 6:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Kirk E. Dineley, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 806E, Bethesda, MD 20892, 301-867-5309, [dineleyke@csr.nih.gov](mailto:dineleyke@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 18, 2026.

**Bruce A. George,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2026-05526 Filed 3-19-26; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Human Genome Research Institute; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council for Human Genome Research.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council for Human Genome Research.

*Date:* May 18-19, 2026.

*Closed:* May 18, 2026, 11:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Human Genome Research Institute, National Institutes of Health, 6700 Rockledge Drive, Suite 1100, Bethesda, MD 20892.

*Meeting Format:* (Hybrid).

*Open:* May 19, 2026, 11:00 a.m. to 5:00 p.m.

*Agenda:* To discuss matters of program relevance and reports of Institute Director and Institute Staff.

*Address:* National Human Genome Research Institute, National Institutes of Health, 6700 Rockledge Drive, Suite 1100, Bethesda, MD 20892.

*Meeting Format:* (Hybrid).

*Contact Person:* Issel Anne Lim, Ph.D., Deputy Director, Division of Extramural Operations, National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Room 3186, Bethesda, MD 20892, [isselanne.lim@nih.gov](mailto:isselanne.lim@nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has procedures at <https://security.nih.gov/>